Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Current Assets (2023 - 2025)

Beta Bionics (BBNX) has disclosed Current Assets for 3 consecutive years, with $267.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 101.55% to $267.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $267.9 million through Dec 2025, up 101.55% year-over-year, with the annual reading at $267.9 million for FY2025, 101.55% up from the prior year.
  • Current Assets hit $267.9 million in Q4 2025 for Beta Bionics, down from $270.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $286.1 million in Q2 2025 to a low of $103.6 million in Q4 2023.
  • Historically, Current Assets has averaged $220.4 million across 3 years, with a median of $264.9 million in 2025.
  • Biggest five-year swings in Current Assets: grew 28.28% in 2024 and later surged 101.55% in 2025.
  • Year by year, Current Assets stood at $103.6 million in 2023, then increased by 28.28% to $132.9 million in 2024, then soared by 101.55% to $267.9 million in 2025.
  • Business Quant data shows Current Assets for BBNX at $267.9 million in Q4 2025, $270.0 million in Q3 2025, and $286.1 million in Q2 2025.